文献速递头颈外科

NCCN推荐治疗后监测与HPV相关口咽鳞癌结局的关联

Association of NCCN-Recommended Posttreatment Surveillance With Outcomes in Patients With HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2019-01-01

该回顾性队列研究纳入233例HPV相关口咽鳞癌患者,评估对NCCN临床随访指南的依从性、复发检出方式及生存获益。结果显示临床监测依从性逐年下降,几乎所有临床检出复发均由患者症状触发,依从指南与全因死亡率无关(HR 0.76,95%CI 0.28-2.05),局部区域复发均在2年内,可挽救复发均在1年内。

要点

  • 临床监测检出的复发多由患者症状触发,而非医生或影像发现。
  • 对NCCN随访指南的依从性与全因死亡率无显著关联(HR 0.76,95%CI 0.28-2.05)。
  • 所有局部区域复发均在2年内,所有可挽救复发均在1年内。

核心结论

  • 在HPV相关口咽鳞癌患者中,临床监测效用有限,多数临床检出复发由患者症状触发。
  • 依从当前NCCN随访计划未显示生存优势,局部区域复发几乎不在2年后检出。
  • 研究结果支持减少该人群的治疗后临床监测。

研究设计与样本

  • 回顾性队列研究,纳入2011年1月1日至2014年4月30日诊断的233例HPV相关口咽鳞癌患者。
  • 采用Cox比例风险回归模型进行多因素分析,NCCN随访依从性作为时间依赖变量。

主要发现

  • 第1年依从率83.0%(180/217),第2年52.7%(106/201),第3年73.4%(141/192),第4年62.3%(96/154),第5年52.9%(45/85)。
  • 共进行3358次临床监测检查,22例患者复发,其中症状导向10例、医生发现1例、影像发现11例。
  • 症状导向复发中5例尝试挽救治疗,研究结束时1例存活;医生发现的1例尝试挽救性颈清扫后死亡。
  • 所有局部区域复发均在前2年内,所有可挽救复发均在第1年内。
  • 多因素Cox模型显示依从NCCN指南对全因死亡率无保护作用(HR 0.76,95%CI 0.28-2.05)。

临床怎么用

  • 对于HPV相关口咽鳞癌治疗后患者,可考虑减少常规临床随访频率。
  • 随访中应重视患者症状报告,因其常为复发早期提示。
  • 局部区域复发监测应集中在治疗后2年内,尤其是第1年。

局限性

  • 回顾性研究设计可能引入选择偏倚和信息偏倚。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: National Comprehensive Cancer Network (NCCN) guidelines recommend routine clinical follow-up as posttreatment surveillance for patients with head and neck cancer (HNC). Human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV-associated OPSCC) is a unique subset of HNC, associated with fewer recurrences and improved survival. The utility of this guideline in this patient population is unknown. OBJECTIVE: To determine adherence to the NCCN clinical follow-up guideline, frequency of recurrence detection method, classified as symptom-directed, physician-detected, or imaging-detected, and survival benefit associated with adherence to the NCCN guideline. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of patients with HPV-associated OPSCC diagnosed between January 1, 2011, and April 30, 2014, at a large integrated health care system. Multivariable analyses were conducted using the Cox proportional hazards regression model, with patient adherence to NCCN visit guidelines constructed as a time-dependent variable. All data analyses were complete on September 1, 2018. EXPOSURES: Posttreatment clinical and imaging surveillance. MAIN OUTCOMES AND MEASURES: Recurrence and overall survival. Secondary outcome was salvage therapy. RESULTS: Of the 233 study patients with HPV-associated OPSCC, the mean (SD) age at diagnosis was 60.5 (8.7) years; 201 (86.3%) were male, 189 (81.1%) were white, and 109 (46.8%) had a positive smoking history. Median follow-up time through recurrence or all-cause mortality was 4.5 years (interquartile range, 3.8-5.6). Patients demonstrated 83.0% (180 of 217) adherence to NCCN surveillance guidelines in year 1, 52.7% (106 of 201) in year 2, 73.4% (141 of 192) in year 3, 62.3% (96 of 154) in year 4, and 52.9% (45 of 85) in year 5. A total of 3358 clinical surveillance examinations were performed with 22 patients having recurrences. There were 10 symptom-directed, 1 physician-detected, and 11 imaging-detected recurrences. Of the symptom-directed recurrences, salvage therapy was attempted in 5; at the study end date, 1 was alive. Salvage neck dissection was attempted in the physician-detected recurrence; this patient subsequently died. All locoregional recurrences occurred within the first 2 years, and all salvageable recurrences within the first year. Adherence to NCCN guidelines was not protective against all-cause mortality in the multivariable Cox proportional hazards regression model (hazard ratio, 0.76; 95% CI, 0.28-2.05). CONCLUSIONS AND RELEVANCE: Among patients with HPV-associated OPSCC, clinical surveillance is of limited utility. Nearly all clinically detected recurrences were elicited by patient symptoms that prompted earlier presentation to the clinician. Adherence to the current schedule does not appear to confer survival advantage, and locoregional recurrences are almost never detected beyond 2 years. These findings support reduction of posttreatment clinical surveillance in this population.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Masroor F, Corpman D, Carpenter DM, et al. Association of NCCN-Recommended Posttreatment Surveillance With Outcomes in Patients With HPV-Associated Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngol Head Neck Surg. 2019. PMID: 31393552. doi:10.1001/jamaoto.2019.1934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。